The acute bacterial skin and skin structure infections treatment market is driven by the growing incidence of skin and skin structure infections. Rising research and developmental activities by pharmaceutical companies and expanding drug pipelines are anticipated to facilitate market growth during the forecast period.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
In June 2022, Basilea Pharmaceutics attained the permission to apply for the approval of its new antibiotic Ceftobiprole. Basilea will apply for approval on the basis of the results of its TARGET study. This drug, once approved, will be in the acute bacterial skin and skin structure infections treatment market.
In December 2021, Nuzyra, an innovative drug, was approved by China’s NMPA for treating patients with ABSSSIs. It is believed to act on a wide range of pathogens responsible for chronic infections. This will also help in the complete treatment at home, thus saving the patient costs.
In July 2021, the FDA also approved Dalvance, a synthetic glycopeptide which will now help treat ABSSSIs in children. It was earlier only approved for adults.
Acute bacterial skin and skin structure infections (ABSSSIs) are chronic skin infections with at least one significant lesion size. These infections are generally associated with skin and soft tissues. These acute bacterial skin and skin infections are of two types- complicated and uncomplicated acute bacterial skin and skin infections.
As the name suggests, complicated infections affect the deeper soft tissue and thus require surgical procedures as a treatment. The causative agents for uncomplicated infections are Streptococcus pyogenes and Staphylococcus aureus. The complicated acute bacterial skin and skin structure infections typically include burns, ulcers, and primary abscesses, while uncomplicated ones include furuncles, superficial abscesses, impetiginous lesions, and cellulitis.
Standard laboratory tests, radiological examinations, and microbiological examinations are often used to diagnose these infections. The treatment for acute bacterial skin and skin structure infections is speculative and depends on the prevalent signs and symptoms and the type of affected location. A broad spectrum of antibiotics is often prescribed, and the patient is monitored for the entire course duration. Antibiotic therapy must be defined based on the type of the pathogen involved and the varied clinical spectrum of disease.
Out of all the prevailing infections, community-associated methicillin-resistant Staphylococcus aureus accounts for the maximum share in the acute bacterial skin and skin structure infections treatment market. The maximum incidence rate of acute bacterial skin and skin structure infections is witnessed in the United States.
According to the acute bacterial skin and skin structure infections market research report, the market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
United States of America
United Arab Emirates
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The acute bacterial skin and skin structure infections treatment market is driven by the rising number of plaque psoriasis diagnosed cases, which was nearly 125 million in 2021. The prevalence of plaque psoriasis disease is likely to grow at a rate of 21% in the forecast period of 2024-2032 and reach approximately 692 million by 2030.
The growth of the market is also facilitated by the rising incidence of skin and skin structure infections. Skin diseases are among the most prevalent issues experienced by people, affecting about one-third of the global population. Skin diseases account for nearly 1.79% of the worldwide burden of diseases.
According to the 2023 Pubmed statistics, 94 million Europeans complain of skin infections, thus indirectly contributing to a significant share of the market.
The most common causative pathogen for acute bacterial skin and skin structure infections is S. Aureus and streptococci, among other gram-positive bacteria. North America and the Asia Pacific account for the maximum share of the acute bacterial skin and skin structure infections treatment market. Based on gender, acute bacterial skin and skin structure infections are more prevalent in men than women.
The key factors contributing to the acute bacterial skin and skin structure infections treatment market growth include increased prevalence rate, increased awareness among communities, advanced research and development activities and increased clinical trials.
There are several limiting factors which hinder the market expansion. Strict regulatory policies by authorities, termination of the patent license, and antibiotic resistance for various strains hamper the market’s overall development.
The COVID-19 pandemic also worsened the symptoms and condition of acute bacterial skin and skin structure infections in patients and thus, leading to prolonged hospitalisation and treatment. Apart from that, the pandemic also affected the drug and pharmaceuticals’ global supply, thus significantly impacting the treatment market share.
Henceforth, the novel product inventions for treatment by pharmaceutical and biotechnological companies are the key factors driving the market forecast.
The United States of America is one of the leading disease treatment markets, accounting for the maximum number of acute skin and skin structure infections globally. In the United States, around 3.3 million patients experienced acute bacterial skin and skin structure infections, leading to an increase in ambulatory care and emergency department visits by 30% and 40%, respectively. This directly leads to the manifold increase in the acute bacterial skin and skin structure infections treatment market.
Acute bacterial skin and skin infections are chronic skin infections affecting the skin and soft tissues. The treatment and management are based on the guidelines published by the World Health Organisation. According to these guidelines, acute bacterial skin and skin infections are divided into two categories: Purulent and Non-Purulent.
Non-purulent acute bacterial skin and skin structure infections include erysipelas and cellulitis, while purulent acute bacterial skin and skin structure infections include abscesses. The different antibiotics are prescribed on the basis and type of the acute bacterial skin and skin structure infections, which are as follows-
According to the treatment algorithm, the treatment schedule lasts for about 7-10 days. The discovered antibiotics generally target both gram-positive and gram-negative bacteria. These antibiotic formulations can be administered by both parenteral, oral, and topical routes.
The different categories of antibiotics available in the acute bacterial skin and skin structure infections treatment market are Beta Lactams, Cyclic Lipopeptides, Fluoroquinolones, Glycopeptides, Glycylcyclines, Lipoglycopeptides, and Oxazolidinones.
Beta lactams are bactericidal in action and are administered parenterally. At the same time, cyclic lipopeptides are broad-spectrum antibiotics exhibiting concentration dependant bactericidal activity and have reversible side effects on discontinuation of treatment.
Fluoroquinolones are used in treating acute bacterial skin and skin structure infections and consist of quinolones, making them active in an acidic environment and can be administered by both oral and parenteral routes.
Glycopeptides, another class of antibiotics, possess bactericidal action against gram-positive and gram-negative bacteria, while glycylcyclines are a broad-spectrum intravenous class exhibiting action against atypical, anaerobic, gram-positive, gram-negative and few multidrug-resistant pathogens.
Oxazolidinones and lipoglycopeptides act only on gram-positive pathogens and are available in oral and intravenous forms.
Of all the available antibiotics classes, Cephalosporins account for a significant share of the acute bacterial skin and skin structure infections treatment market, followed by Penicillin, Quinolones, Clindamycin, and Tetracyclines.
Patients suffering from acute bacterial skin and skin structure infections opt for hospital visits, ambulatory services, or emergency department visits. The patients can be treated both as inpatients and outpatients. Inpatient care requires the patient to stay in the hospital while outpatient care does not demand any hospital stay.
The primary aim of healthcare professionals is to minimise inpatient stays and hospital admissions. Generally, patients with symptoms like lack of aggravation of comorbidities, no signs of sepsis, and low suspicion are manageable as outpatients.
A surgical procedure is another treatment option for acute bacterial skin and skin structure infections. During the surgery, the doctors aim to remove all the foreign agents and drain the infected fluids, thus helping in the eradication ABSSSIs.
The management of acute bacterial skin and skin structure infections is based on two critical objectives: early switch therapy and early discharge.
In early switch therapy, physicians generally aim to switch patients from intravenous to oral route, while in early discharge treatment, the main objective of the physician is to complete the entire treatment after hospital discharge.
Scientists have also discovered some outpatients’ parenteral antimicrobial therapy, which recommends selecting and observing patients and applying antimicrobial treatment in community settings.
Through the acute bacterial skin and skin structure infections treatment market analysis, it was demonstrated that a specific population across the world is more susceptible to these infections than others. This specific population includes elderly people and patients with other co-morbidities like renal impairment, immunosuppression, and cardiovascular diseases. Thus, an increase in this population also drives the growth of the acute bacterial skin and skin structure infections treatment market.
The Food and Drug Administration works endlessly on clinical trials and programs for acute bacterial skin and skin structure infections. According to the new FDA guidelines, the central ideology behind the clinical trials of ABSSSIs drugs and therapy is the application of an active comparator antibacterial drug and medication.
Scientists are working on several clinical trials, which will be accessible in the acute bacterial skin and skin structure treatment market in the coming years.
Scientists are also developing new drugs and medications that are antibiotic resistant and have potent action. Several ongoing clinical trials are emerging as a growth driving factor for the acute bacterial skin and skin structure infections treatment market.
The report gives an in-depth analysis of the key players involved in the market, sponsors manufacturing the drugs, putting them through trials to get FDA approvals. The acute bacterial skin and skin structure infections treatment companies included in the market are as follows :
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Infection Type||
|Breakup by Route of Administration||
|Breakup by Treatment Channel||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
3.1 Acute Bacterial Skin and Skin Structure Infections Overview
3.2 Guidelines and Stages
3.4 Screening and Diagnosis
3.5 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Current Scenario Evaluation and Regulatory Framework
5.1 Emerging Therapies and Clinical Trials
5.2 Patent Landscape
5.2.1 Patent Overview
126.96.36.199 Patent Status and Expiry
188.8.131.52 Timelines from Drug Development to Commercial Launch
184.108.40.206 New Drug Application
220.127.116.11.1 Documentation and Approval Process
5.3 Cost of Treatment
5.4 Regulatory Framework
5.4.1 Regulatory Overview
18.104.22.168 US FDA
22.214.171.124 EU EMA
126.96.36.199 INDIA CDSCO
188.8.131.52 JAPAN PMDA
6 Challenges and Unmet Needs
6.1 Treatment Pathway Challenges
6.2 Compliance and Drop-Out Analysis
6.3 Awareness and Prevention Gaps
7 Global Acute Bacterial Skin and Skin Structure Infections Treatment Market
7.1 Global Acute Bacterial Skin and Skin Structure Infections Treatment Market Overview
7.2 Global Acute Bacterial Skin and Skin Structure Infections Treatment Market Analysis
7.2.1 Market Overview
184.108.40.206 Global Acute Bacterial Skin and Skin Structure Infections Treatment Market Historical Value (2017-2023)
220.127.116.11 Global Acute Bacterial Skin and Skin Structure Infections Treatment Market Forecast Value (2024-2032)
7.3 Global Acute Bacterial Skin and Skin Structure Infections Treatment Market by Infection Type
7.3.1 Market Overview
18.104.22.168 Hospital Acquired
22.214.171.124 Community Acquired
7.4 Global Acute Bacterial Skin and Skin Structure Infections Treatment Market by Route of Administration
7.4.1 Market Overview
7.5 Global Acute Bacterial Skin and Skin Structure Infections Treatment Market by Treatment Channel
7.5.1 Market Overview
7.6 Global Acute Bacterial Skin and Skin Structure Infections Treatment Market by Region
7.6.1 Market Overview
126.96.36.199 North America
188.8.131.52 Asia Pacific
184.108.40.206 Latin America
220.127.116.11 Middle East and Africa
8 North America Acute Bacterial Skin and Skin Structure Infections Treatment Market
8.1 Market Share by Country
8.2 United States of America
8.2.1 Historical Trend (2017-2023)
8.2.2 Forecast Trend (2024-2032)
8.3.1 Historical Trend (2017-2023)
8.3.2 Forecast Trend (2024-2032)
9 Europe Acute Bacterial Skin and Skin Structure Infections Treatment Market
9.1 Market Share by Country
9.2 United Kingdom
9.2.1 Historical Trend (2017-2023)
9.2.2 Forecast Trend (2024-2032)
9.3.1 Historical Trend (2017-2023)
9.3.2 Forecast Trend (2024-2032)
9.4.1 Historical Trend (2017-2023)
9.4.2 Forecast Trend (2024-2032)
9.5.1 Historical Trend (2017-2023)
9.5.2 Forecast Trend (2024-2032)
10 Asia Pacific Acute Bacterial Skin and Skin Structure Infections Treatment Market
10.1 Market Share by Country
10.2.1 Historical Trend (2017-2023)
10.2.2 Forecast Trend (2024-2032)
10.3.1 Historical Trend (2017-2023)
10.3.2 Forecast Trend (2024-2032)
10.4.1 Historical Trend (2017-2023)
10.4.2 Forecast Trend (2024-2032)
10.5.1 Historical Trend (2017-2023)
10.5.2 Forecast Trend (2024-2032)
10.6.1 Historical Trend (2017-2023)
10.6.2 Forecast Trend (2024-2032)
11 Latin America Acute Bacterial Skin and Skin Structure Infections Treatment Market
11.1 Market Share by Country
11.2.1 Historical Trend (2017-2023)
11.2.2 Forecast Trend (2024-2032)
11.3.1 Historical Trend (2017-2023)
11.3.2 Forecast Trend (2024-2032)
11.4.1 Historical Trend (2017-2023)
11.4.2 Forecast Trend (2024-2032)
12 Middle East and Africa Acute Bacterial Skin and Skin Structure Infections Treatment Market
12.1 Market Share by Country
12.2 Saudi Arabia
12.2.1 Historical Trend (2017-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 United Arab Emirates
12.3.1 Historical Trend (2017-2023)
12.3.2 Forecast Trend (2024-2032)
12.4.1 Historical Trend (2017-2023)
12.4.2 Forecast Trend (2024-2032)
12.5 South Africa
12.5.1 Historical Trend (2017-2023)
12.5.2 Forecast Trend (2024-2032)
13 Global Acute Bacterial Skin and Skin Structure Infections Treatment Market Dynamics
13.1 Market Drivers and Constraints
13.2 SWOT Analysis
13.3 Porter’s Five Forces Model
13.4 Key Demand Indicators
13.5 Key Price Indicators
13.6 Industry Events, Initiatives, and Trends
13.7 Value Chain Analysis
14 Supplier Landscape
14.1 Paratek Pharmaceuticals, Inc.
14.1.1 Company Overview
14.1.2 Product Portfolio
14.1.3 Demographic Reach and Achievements
14.1.4 Mergers and Acquisitions
14.2 Merck & Co., Inc.
14.2.1 Company Overview
14.2.2 Product Portfolio
14.2.3 Demographic Reach and Achievements
14.2.4 Mergers and Acquisitions
14.3 Melinta Therapeutics
14.3.1 Company Overview
14.3.2 Product Portfolio
14.3.3 Demographic Reach and Achievements
14.3.4 Mergers and Acquisitions
14.4 AbbVie Inc.
14.4.1 Company Overview
14.4.2 Product Portfolio
14.4.3 Demographic Reach and Achievements
14.4.4 Mergers and Acquisitions
14.5 Novartis AG
14.5.1 Company Overview
14.5.2 Product Portfolio
14.5.3 Demographic Reach and Achievements
14.5.4 Mergers and Acquisitions
14.6 Glenmark Pharmaceuticals Ltd.
14.6.1 Company Overview
14.6.2 Product Portfolio
14.6.3 Demographic Reach and Achievements
14.6.4 Mergers and Acquisitions
14.7 Teva Pharmaceutical Industries Ltd.
14.7.1 Company Overview
14.7.2 Product Portfolio
14.7.3 Demographic Reach and Achievements
14.7.4 Mergers and Acquisitions
14.8 Sun Pharmaceutical Industries Limited
14.8.1 Company Overview
14.8.2 Product Portfolio
14.8.3 Demographic Reach and Achievements
14.8.4 Mergers and Acquisitions
14.9 Idera Pharmaceuticals, Inc.
14.9.1 Company Overview
14.9.2 Product Portfolio
14.9.3 Demographic Reach and Achievements
14.9.4 Mergers and Acquisitions
14.10 Intas Pharmaceuticals
14.10.1 Company Overview
14.10.2 Product Portfolio
14.10.3 Demographic Reach and Achievements
14.10.4 Mergers and Acquisitions
14.11 Agiliti, Inc.
14.11.1 Company Overview
14.11.2 Product Portfolio
14.11.3 Demographic Reach and Achievements
14.11.4 Mergers and Acquisitions
14.12 Zydus Lifesciences Limited
14.12.1 Company Overview
14.12.2 Product Portfolio
14.12.3 Demographic Reach and Achievements
14.12.4 Mergers and Acquisitions
15 Global Acute Bacterial Skin and Skin Structure Infections Treatment Market- Drug Distribution Model (Additional Insight)
15.2 Potential Distributors
15.3 Key Parameters for Distribution Partner Assessment
16 Payment Methods (Additional Insight)
16.1 Government Funded
16.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
Based on the infection type, the market is divided into hospital acquired and community acquired.
Based on the route of administration, the market is divided into oral, topical, and parenteral, among others.
The treatment channels in this market can be divided into private and public.
The United States of America accounts for the maximum share owing to the higher prevalence of skin and skin structure infections.
First-generation cephalosporins are the most effective antibiotics for treating ABSSSIs.
The two most common bacteria in skin infections are Streptococcus pyogenes and Staphylococcus aureus.
Acute bacterial skin and skin structure infection is an infection of the skin and associated tissues caused by bacteria. It can be treated with the help of antibiotics.
Antibiotic resistance is the limiting factor which hampers the treatment market growth.
The different categories of antibiotics used for treating ABSSSIs are Beta Lactams, Cyclic Lipopeptides, Fluoroquinolones, Glycopeptides, Glycylcyclines, Lipoglycopeptides, and Oxazolidinones.
These infections are often treated with antibiotics. If the strain of the bacteria is resistant to treatment, surgical intervention may be required.
Dalvance is the latest approved drug by USFDA for the treatment of SABS and ABSSSIs.
The key companies involved in the ABSSSIs market are Paratek Pharmaceuticals, Inc., Merck & Co., Inc., Melinta Therapeutics, AbbVie Inc., Sandoz International GmbH, Glenmark Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Aceragen, Inc. (Arrevus, Inc.), Accord Healthcare, Intas Pharmaceuticals, Fresenius SE & Co. KGaA, and Zydus Lifesciences Limited, among others.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.